z-logo
open-access-imgOpen Access
IL‐36 γ and IL‐36Ra Reciprocally Regulate NSCLC Progression by Modulating GSH Homeostasis and Oxidative Stress‐Induced Cell Death
Author(s) -
Wang Peng,
Yang Wei,
Guo Hao,
Dong HongPeng,
Guo YuYao,
Gan Hu,
Wang Zou,
Cheng Yongbo,
Deng Yu,
Xie Shizhe,
Yang Xinglou,
Lin Dandan,
Zhong Bo
Publication year - 2021
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202101501
Subject(s) - oxidative stress , carcinogenesis , glutathione , reactive oxygen species , homeostasis , cytokine , cancer research , tumor progression , cancer , chemistry , immunology , biology , microbiology and biotechnology , medicine , endocrinology , biochemistry , enzyme
The balance between antioxidants and reactive oxygen species (ROS) critically regulates tumor initiation and progression. However, whether and how the tumor‐favoring redox status is controlled by cytokine networks remain poorly defined. Here, it is shown that IL‐36 γ and IL‐36Ra reciprocally regulate the progression of non‐small cell lung cancer (NSCLC) by modulating glutathione metabolism and ROS resolution. Knockout, inhibition, or neutralization of IL‐36 γ significantly inhibits NSCLC progression and prolongs survival of the Kras LSL‐G12D/+ Tp53 fl/fl and Kras LSL‐G12D/+ Lkb1 fl/fl mice after tumor induction, whereas knockout of IL‐36Ra exacerbates tumorigenesis in these NSCLC mouse models and accelerates death of mice. Mechanistically, IL‐36 γ directly upregulates an array of genes involved in glutathione homeostasis to reduce ROS and prevent oxidative stress‐induced cell death, which is mitigated by IL‐36Ra or IL‐36 γ neutralizing antibody. Consistently, IL‐36 γ staining is positively and negatively correlated with glutathione biosynthesis and ROS in human NSCLC tumor biopsies, respectively. These findings highlight essential roles of cytokine networks in redox for tumorigenesis and provide potential therapeutic strategy for NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here